Spiro Rombotis - Cyclacel Pharmaceuticals CEO and President and Executive Director

CYCC Stock  USD 0.37  0.03  6.75%   

CEO

Mr. Spiro George Rombotis serves as President, Chief Executive Officer, Director of Cyclacel Pharmaceuticals Inc. Mr. Rombotis has served as a director of the Company since March 2006 since 2006.
Age 65
Tenure 18 years
Professional MarksMBA
Address 200 Connell Drive, Berkeley Heights, NJ, United States, 07922
Phone908 517 7330
Webhttps://www.cyclacel.com
Rombotis joined Cyclacel in August 1997 as our first Chief Executive Officer and has over 30 years of experience with pharmaceutical and biotechnology companies. He was previously Vice President of International Operations and Business Development; Managing Director, Europe; and Director, Japanese joint venture, at The Liposome Company, Inc. He also served as Vice President of Pharmaceuticals for Central and Eastern Europe and as Director of International Marketing at BristolMyers Squibb Company. He was Head of European Marketing and Sales, Head of Corporationrationrationrate Development and one of the first employees of Centocor, Inc. and worked in Business Development at Novartis AG. He holds a B.A. from Williams College and an M.B.A. and Master’s degree in Hospital Management with honors, from the Kellogg Graduate School of Management, where he serves on the Kellogg Biotech Advisory Board. He also serves on the Board of Trustees of BioNJ, the biotechnology industry trade group in New Jersey.

Spiro Rombotis Latest Insider Activity

Tracking and analyzing the buying and selling activities of Spiro Rombotis against Cyclacel Pharmaceuticals stock is an integral part of due diligence when investing in Cyclacel Pharmaceuticals. Spiro Rombotis insider activity provides valuable insight into whether Cyclacel Pharmaceuticals is net buyers or sellers over its current business cycle. Note, Cyclacel Pharmaceuticals insiders must abide by specific rules, including filing SEC forms every time they buy or sell Cyclacel Pharmaceuticals'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.

Cyclacel Pharmaceuticals Management Efficiency

The company has return on total asset (ROA) of (1.0253) % which means that it has lost $1.0253 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (5.7069) %, meaning that it created substantial loss on money invested by shareholders. Cyclacel Pharmaceuticals' management efficiency ratios could be used to measure how well Cyclacel Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Tangible Assets is expected to grow to -2.43. The current year's Return On Capital Employed is expected to grow to -37.55. At present, Cyclacel Pharmaceuticals' Non Currrent Assets Other are projected to increase significantly based on the last few years of reporting. The current year's Other Current Assets is expected to grow to about 4.3 M, whereas Total Assets are forecasted to decline to about 8.4 M.
Cyclacel Pharmaceuticals currently holds 37 K in liabilities with Debt to Equity (D/E) ratio of 0.0, which may suggest the company is not taking enough advantage from borrowing. Cyclacel Pharmaceuticals has a current ratio of 6.25, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Cyclacel Pharmaceuticals' use of debt, we should always consider it together with its cash and equity.

Similar Executives

Found 10 records

CEO Age

Kevin KochEdgewise Therapeutics
64
Nevan JDRezolute
57
BAO BChEliem Therapeutics
48
Mark ManfrediIkena Oncology
53
Jason OkazakiAssembly Biosciences
48
Samir MDAkari Therapeutics PLC
55
Rachelle JacquesAkari Therapeutics PLC
53
Barry PharmDConnect Biopharma Holdings
67
LLM JDTempest Therapeutics
54
Teofilo MBAPulmatrix
54
Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. Cyclacel Pharmaceuticals, Inc. is headquartered in Berkeley Heights, New Jersey. Cyclacel Pharmaceuti operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. Cyclacel Pharmaceuticals (CYCC) is traded on NASDAQ Exchange in USA. It is located in 200 Connell Drive, Berkeley Heights, NJ, United States, 07922 and employs 7 people. Cyclacel Pharmaceuticals is listed under Biotechnology category by Fama And French industry classification.

Management Performance

Cyclacel Pharmaceuticals Leadership Team

Elected by the shareholders, the Cyclacel Pharmaceuticals' board of directors comprises two types of representatives: Cyclacel Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Cyclacel. The board's role is to monitor Cyclacel Pharmaceuticals' management team and ensure that shareholders' interests are well served. Cyclacel Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Cyclacel Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
Gill Christie, Director Resources
Mark MD, Senior Officer
Spiro Rombotis, CEO and President and Executive Director
Robert Westwood, Head Devel
Brian MD, Interim Director
Paul McBarron, COO, CFO, Principal Accounting Officer, Executive VP of Fin. and Admin., Secretary and Executive Director
Grace Kim, Investor Executive

Cyclacel Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Cyclacel Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Cyclacel Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Cyclacel Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Cyclacel Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Cyclacel Pharmaceuticals Stock:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cyclacel Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.
For information on how to trade Cyclacel Stock refer to our How to Trade Cyclacel Stock guide.
You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cyclacel Pharmaceuticals. If investors know Cyclacel will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cyclacel Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(27.40)
Revenue Per Share
0.044
Quarterly Revenue Growth
(0.99)
Return On Assets
(1.03)
Return On Equity
(5.71)
The market value of Cyclacel Pharmaceuticals is measured differently than its book value, which is the value of Cyclacel that is recorded on the company's balance sheet. Investors also form their own opinion of Cyclacel Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Cyclacel Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cyclacel Pharmaceuticals' market value can be influenced by many factors that don't directly affect Cyclacel Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cyclacel Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cyclacel Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cyclacel Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.